AI Summary
We reviewed 11 live results for mvasi (bevacizumab awwb) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilar and Oncology.
Comparison Table
Recommended
Mvasi
Source: Amgen Biotechnology Singapore Pte Ltd
Description
Mvasi is a bevacizumab biosimilar referencing Avastin, used in Singapore for the treatment of several cancer types including colorectal, lung, and breast cancer. It works as an angiogenesis inhibitor, preventing the growth of blood vessels that feed tumors.
Best for
colorectal cancer treatment, lung cancer management and targeted oncology therapy
View Details
Rating
Mvasi (bevacizumab)
Source: Amgen
Description
Mvasi is a biosimilar to the reference drug Avastin, containing the active substance bevacizumab. This oncology treatment is administered as an intravenous infusion to patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, and other advanced cancers. In Malaysia, it is registered under MAL19086005ACZ and is supplied in 100 mg and 400 mg vials as a concentrate for solution. As a biosimilar, it provides a highly similar clinical profile to its reference product, supporting cancer management and therapy accessibility.
Best for
metastatic colorectal cancer, non-small cell lung cancer patients, biosimilar treatment options, intravenous oncology therapy and hospital-based cancer care
View Details
Rating
MVASI (bevacizumab-awwb)
Source: Amgen Inc.
Description
MVASI is a recombinant humanized monoclonal antibody that serves as a Vascular Endothelial Growth Factor (VEGF) inhibitor and biosimilar to Avastin. It is provided as a sterile, preservative-free solution for intravenous infusion in 100 mg/4 mL and 400 mg/16 mL single-dose vials. This oncology treatment is indicated for patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (mRCC), cervical cancer, and various stages of ovarian cancer.
Best for
oncology patients, metastatic colorectal cancer treatment, NSCLC first-line therapy, recurrent glioblastoma management and combination chemotherapy regimens
View Details
Rating
| Compare | Mvasi | Mvasi (bevacizumab) | MVASI (bevacizumab-awwb) |
|---|---|---|---|
| Source | Amgen Biotechnology Singapore Pte Ltd | Amgen | Amgen Inc. |
| Description | Mvasi is a bevacizumab biosimilar referencing Avastin, used in Singapore for the treatment of several cancer types including colorectal, lung, and breast cancer. It works as an angiogenesis inhibitor, preventing the growth of blood vessels that feed tumors. | Mvasi is a biosimilar to the reference drug Avastin, containing the active substance bevacizumab. This oncology treatment is administered as an intravenous infusion to patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, and other advanced cancers. In Malaysia, it is registered under MAL19086005ACZ and is supplied in 100 mg and 400 mg vials as a concentrate for solution. As a biosimilar, it provides a highly similar clinical profile to its reference product, supporting cancer management and therapy accessibility. | MVASI is a recombinant humanized monoclonal antibody that serves as a Vascular Endothelial Growth Factor (VEGF) inhibitor and biosimilar to Avastin. It is provided as a sterile, preservative-free solution for intravenous infusion in 100 mg/4 mL and 400 mg/16 mL single-dose vials. This oncology treatment is indicated for patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (mRCC), cervical cancer, and various stages of ovarian cancer. |
| Best for | colorectal cancer treatment, lung cancer management and targeted oncology therapy | metastatic colorectal cancer, non-small cell lung cancer patients, biosimilar treatment options, intravenous oncology therapy and hospital-based cancer care | oncology patients, metastatic colorectal cancer treatment, NSCLC first-line therapy, recurrent glioblastoma management and combination chemotherapy regimens |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Mvasi from Amgen Biotechnology Singapore Pte Ltd."
I picked this because Mvasi is a widely registered bevacizumab biosimilar in Singapore indicated for multiple common cancer types and supported by medical guidelines.
Share this search
Related Finds